Lonapegsomatropin (TransCon hGH)
Pediatric Growth Hormone Deficiency
ApprovedBLA approved in China (2024)
Key Facts
Indication
Pediatric Growth Hormone Deficiency
Phase
Approved
Status
BLA approved in China (2024)
Company
About VISEN Pharmaceuticals
A China-focused biopharma company developing long-acting endocrine therapies using TransCon technology.
View full company profileTherapeutic Areas
Other Pediatric Growth Hormone Deficiency Drugs
| Drug | Company | Phase |
|---|---|---|
| NGENLA™ (somatrogon) | Opko Health | Market |
| NGENLA (somatropin‑CTP) | Opko Biologis | Approved |
| Long-acting rhGH (New Formulations) | Changchun High-Tech Industry | Development |
| TransCon hGH (lonapegsomatropin) | Ascendis Pharma | Approved |